Patents Examined by Alana Harris Dent
  • Patent number: 10227388
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: June 30, 2016
    Date of Patent: March 12, 2019
    Assignee: Immatics Biotechnologies GMBH
    Inventors: Andrea Mahr, Toni Weinschenk, Helen Hoerzer, Oliver Schoor, Jens Fritsche, Harpreet Singh
  • Patent number: 10196435
    Abstract: Provided is an isolated recombinant polypeptide comprising an immunoglobulin domain and a canine OX40L extracellular domain polypeptide fragment or a biological equivalent thereof and compositions comprising: an isolated recombinant polypeptide comprising an immunoglobulin domain and a canine OX40L extracellular domain polypeptide fragment; and a pharmaceutically acceptable carrier. Also provided are methods for treating or ameliorating the symptoms of cancer in a canine comprising administering an effective amount of the isolated recombinant polypeptide of the disclosure and/or a composition of the disclosure to a canine in need thereof.
    Type: Grant
    Filed: November 17, 2014
    Date of Patent: February 5, 2019
    Assignee: University of Southern California
    Inventors: Alan L. Epstein, Peisheng Hu
  • Patent number: 10197572
    Abstract: The present invention relates to a method and a kit and antibodies utilized therein, allowing to distinguish between leukemia cells resistant to and leukemia cells susceptible to differentiation induced by deltanoids.
    Type: Grant
    Filed: June 12, 2015
    Date of Patent: February 5, 2019
    Assignee: WROCLAWSKIE CENTRUM BADAN EIT+ SP. Z O.O.
    Inventors: Ewa Marcinkowska, Aleksandra Marchwicka, Filip Radom, Marta Matusiewicz, Piotr Jakimowicz, Filip Jelen, Maciej Mazurek
  • Patent number: 10184942
    Abstract: The invention pertains to biomarkers for clinical detection of malignancies, especially for early detection of cancers. More specifically, this invention pertains to the role of Natriuretic Peptide Receptor A (NPRA) in cancer (e.g., tumor) progression. Thus, the invention includes materials and methods for the detection and prognosis of malignancies. The invention also pertains to methods for treating malignancies.
    Type: Grant
    Filed: March 16, 2012
    Date of Patent: January 22, 2019
    Assignee: UNIVERSITY OF SOUTH FLORIDA
    Inventors: Subhra Mohapatra, Shyam Mohapatra
  • Patent number: 10179935
    Abstract: Early detection of tumors is a major determinant of survival of patients suffering from tumors, including gastric tumors. Members of the GTM gene family can be over-expressed in gastric tumor tissue and other tumor tissue, and thus can be used as markers for gastric and other types of cancer. GTM proteins can be released from cancer cells, and can reach sufficiently high concentrations in the serum and/or other fluids to permit their detection. Thus, methods and test kits for detection and quantification of GTM can provide a valuable tool for diagnosis of gastric cancer.
    Type: Grant
    Filed: July 16, 2004
    Date of Patent: January 15, 2019
    Assignee: PACIFIC EDGE LIMITED
    Inventors: Parry John Guilford, Andrew John Holyoake
  • Patent number: 10172925
    Abstract: The object aims to provide: a novel tumor antigen; a novel therapeutic agent useful in a method for treating a malignant neoplasm by utilizing the tumor antigen; and a tumor antigen which can be used as the therapeutic agent. Thus, disclosed are: a novel tumor antigen which has an epitope capable of inducing a Th1 cell which is a CD4-positive T cell specific to Survivin; and use of the tumor antigen. Specifically disclosed is a polypeptide which comprises an amino acid sequence depicted in SEQ ID NO:17 or the like and has an activity to cause the production of a cytokine by a Th cell that is a cell specific to Survivin. The peptide can induce a Th cell that is specific to Survivin and can cause the production of a cytokine by the Sur/Th cell when the peptide is incubated together with an antigen-presenting cell and a CD4-positive T cell.
    Type: Grant
    Filed: January 22, 2016
    Date of Patent: January 8, 2019
    Assignee: Tella, Inc.
    Inventor: Takashi Nishimura
  • Patent number: 10159726
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: August 26, 2016
    Date of Patent: December 25, 2018
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Andrea Mahr, Toni Weinschenk, Oliver Schoor, Jens Fritsche, Harpreet Singh
  • Patent number: 10150801
    Abstract: The present disclosure provides recombinant polypeptides, nucleic acids encoding the recombinant polypeptides and methods for using these polypeptides and/or nucleic acids in enhancing or inducing an immune response in a subject in need thereof. The present disclosure also provides methods of treating a cell proliferative disorder, such as cancer, by administering the disclosed polypeptides and/or nucleic acids to a subject in need thereof.
    Type: Grant
    Filed: December 27, 2017
    Date of Patent: December 11, 2018
    Assignee: Imunami Laboratories Pte. Ltd.
    Inventors: Ya-Huei Chen, Ting-Long Lin
  • Patent number: 10107817
    Abstract: The present disclosure relates to an oligopeptide which is highly specific to an ovarian cancer. The oligopeptide includes an amino acid sequence of SEQ ID NO: 1. The present disclosure also relates to a test kit including the oligopeptide for detecting ovarian cancer and an ovarian cancer detection method by using the oligopeptide.
    Type: Grant
    Filed: January 20, 2017
    Date of Patent: October 23, 2018
    Assignee: NATIONAL TSING HUA UNIVERSITY
    Inventors: Gwo-Bin Lee, Lien-Yu Hung, Chih-Hung Wang, Chien-Yu Fu, Wen-Bin Lee
  • Patent number: 10098950
    Abstract: This disclosure provides peptides which have a strong affinity for the checkpoint receptor “programmed death 1” (PD-1). These peptides block the interaction of PD-1 with its ligand PD-L1 and can therefore be used for various therapeutic purposes, such as inhibiting the progression of a hyperproliferative disorder, including cancer, treating infectious diseases, enhancing a response to vaccination, and treating sepsis.
    Type: Grant
    Filed: September 15, 2017
    Date of Patent: October 16, 2018
    Assignee: Leidos, Inc.
    Inventors: Gabriel M. Gutierrez, Vinayaka Kotraiah, James Pannucci, Ramses Ayala
  • Patent number: 10077296
    Abstract: The instant invention provides compositions for the treatment of cancer. Specifically, the invention provides polypeptides and nucleic acid molecules comprising tumor-associated embryonic antigens, e.g., OFA-iLRP, and chemoattractant ligands, e.g., a proinflammatory chemokine such as MIP3?/CCL20 or ?-defensin mDF2?. The invention further provides cancer vaccines and methods for treating subjects having, or at risk of developing, cancer.
    Type: Grant
    Filed: August 16, 2012
    Date of Patent: September 18, 2018
    Assignee: The United States of America, as represented by the Secretary, Department of Health & Human Services
    Inventors: Bira Arya, Dan Longo, Igor Espinoza-Delgardo
  • Patent number: 10058598
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: December 9, 2016
    Date of Patent: August 28, 2018
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Andrea Mahr, Toni Weinschenk, Colette Song, Oliver Schoor, Jens Fritsche, Harpreet Singh
  • Patent number: 10035838
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: April 17, 2017
    Date of Patent: July 31, 2018
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Annika Sonntag, Toni Weinschenk, Andrea Mahr, Oliver Schoor, Jens Fritsche, Harpreet Singh
  • Patent number: 10035981
    Abstract: This invention provides an anti-cancer immunogenic agent(s) (e.g. vaccines) that elicit an immune response specifically directed against renal cell cancers expressing a G250 antigenic marker. Preferred immunogenic agents comprise a chimeric molecule comprising a kidney cancer specific antigen (G250) attached to a granulocyte-macrophage colony stimulating factor (GM-CSF). The agents are useful in a wide variety of treatment modalities including, but not limited to protein vaccination, DNA vaccination, and adoptive immunotherapy.
    Type: Grant
    Filed: July 1, 2016
    Date of Patent: July 31, 2018
    Assignee: The Regents of the University of California
    Inventors: Arie Belldegrun, Cho-Lea Tso
  • Patent number: 10023855
    Abstract: A fusion protein including N-terminal domain of a fusion partner at N-terminal and C-terminal domain of RET protein at C-terminal, a fusion gene encoding the fusion protein, and a use of the fusion protein or the fusion gene as a diagnosing marker for a cancer, are provided.
    Type: Grant
    Filed: October 30, 2012
    Date of Patent: July 17, 2018
    Assignees: Macrogen, Inc., Macrogen Corp.
    Inventors: Young-Seok Ju, Jeong-Sun Seo, Eun-Hee Kim
  • Patent number: 10018639
    Abstract: The present invention relates to a method for the accurate, rapid and sensitive detection of breast or ovarian cancers from body fluid samples of a mammalian subject and related assay, kits and peptides suitable for such a method.
    Type: Grant
    Filed: September 23, 2011
    Date of Patent: July 10, 2018
    Assignee: BARD1 LIFE SCIENCES LIMITED
    Inventors: Solomzi Makohliso, Irmgard Irminger-Finger, Fernando Herrera
  • Patent number: 9969789
    Abstract: CD47+ disease cells, such as CD47+ cancer cells, are treated with an agent that blocks signalling via the SIRP?/CD47 axis. The agent is a human SIRP? fusion protein that displays negligible CD47 agonism and negligible red blood cell binding. The fusion protein comprises an IgV domain from variant 2 of human SIRP?, and an Fc having effector function. The IgV domain binds human CD47 with an affinity that is at least five fold greater than the affinity of the entire extracellular region of human SIRP?. The fusion protein is at least 5 fold more potent than a counterpart lacking effector function.
    Type: Grant
    Filed: December 17, 2013
    Date of Patent: May 15, 2018
    Assignee: TRILLIUM THERAPEUTICS INC.
    Inventors: Robert Adam Uger, Penka Slavtcheva Slavova-Petrova, Xinli Pang
  • Patent number: 9963517
    Abstract: Compositions and methods useful for detecting and treating cancers which express the HER4 JM-a isoform are disclosed.
    Type: Grant
    Filed: November 19, 2015
    Date of Patent: May 8, 2018
    Assignees: Genentech, Inc., University of Turku
    Inventors: Mark X. Sliwkowski, Klaus Elenius, Maija Hollmen
  • Patent number: 9901629
    Abstract: A method of treating a patient who has melanoma includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has melanoma. A method of treating a patient who has melanoma includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the melanoma.
    Type: Grant
    Filed: June 30, 2017
    Date of Patent: February 27, 2018
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Annika Sonntag, Toni Weinschenk, Andrea Mahr, Oliver Schoor, Jens Fritsche, Harpreet Singh
  • Patent number: 9902778
    Abstract: The invention relates to the treatment and/or prevention of tumor diseases associated with cells expressing CLDN6, in particular cancer and cancer metastasis using antibodies which bind to CLDN6. The present application demonstrates that the binding of antibodies to CLDN6 on the surface of tumor cells is sufficient to inhibit growth of the tumor and to prolong survival and extend the lifespan of tumor patients. Furthermore, binding of antibodies to CLDN6 is efficient in inhibiting growth of CLDN6 positive germ cell tumors such as teratocarcinomas or embryonal carcinomas, in particular germ cell tumors of the testis.
    Type: Grant
    Filed: July 8, 2016
    Date of Patent: February 27, 2018
    Assignees: Ganymed Pharmaceuticals AG, Johannes Gutenberg-Universitat Mainz
    Inventors: Ugur Sahin, Ozlem Tureci, Michael Koslowski, Korden Walter, Maria Kreuzberg, Sylvia Luxen